LILRB2 Promotes CAR T-cell Dysfunction and Represents a Therapeutic Target in Acute Myeloid Leukemia
This study identifies LILRB2 as a key immunosuppressive receptor expressed on AML blasts and myeloid cells that impairs CAR T-cell function, demonstrating that targeting LILRB2 via antibody blockade or anti-LILRB2 CAR T cells effectively restores anti-tumor immunity and eradicates leukemia in preclinical models without toxicity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Acute myeloid leukemia is a fast-moving cancer of the blood and bone marrow, where the body's factory for making blood cells becomes clogged with immature, useless cells. For decades, doctors have struggled to find a way to clear this factory without destroying the healthy workers needed to keep the body running. In recent years, a powerful new treatment called CAR T-cell therapy has changed the game for some blood cancers. This approach takes a patient's own immune cells, engineers them in a lab to recognize and hunt down cancer, and puts them back into the body. While this method has saved lives in other types of leukemia, it has faced a stubborn wall when applied to acute myeloid leukemia. The cancer cells are often too good at hiding, and the environment they create around them is designed to shut down the immune system, leaving the engineered soldiers confused, exhausted, and ineffective.
A team of researchers at the University Hospital Zurich has now identified a specific molecular switch that helps the leukemia cells pull this off. They found that a protein called LILRB2, which sits on the surface of many leukemia cells, acts like a "do not disturb" sign for the immune system. When the engineered T-cells try to attack, this protein sends a signal that tells the T-cells to stand down, effectively blunting their ability to fight. The researchers discovered that this protein is found on the cancer cells in about 40 percent of patients, but it is largely missing from the healthy stem cells that are needed to rebuild the blood system after treatment. This distinction is crucial because it suggests a way to target the cancer without accidentally wiping out the patient's ability to recover.
To understand how this protein works, the scientists first looked at the behavior of T-cells when they were placed in a dish with leukemia cells that had high levels of LILRB2. They observed that the T-cells did not immediately stop working, but over time, they began to lose their strength. Instead of multiplying and attacking, these cells became tired and aged prematurely, a state known as senescence. They stopped producing the chemical signals needed to coordinate an attack and began to express markers of exhaustion. The researchers confirmed this in mice, showing that when the leukemia cells had this protein, the engineered T-cells failed to clear the cancer, and the animals did not survive as long. However, when the researchers blocked this protein with an antibody, the T-cells regained some of their fighting ability, proving that the protein was indeed the cause of the shutdown.
The team then took a bold step and designed a new type of CAR T-cell that was specifically built to recognize and destroy LILRB2. They created these cells using a non-viral method, which is a safer and more cost-effective way to insert the necessary genetic instructions. When they tested these new cells against leukemia samples from patients, they found that the cells could kill the cancer effectively. In experiments using mice, the treatment cleared the leukemia from the blood, bone marrow, and spleen, and the mice survived significantly longer than those receiving standard care. Importantly, the treatment did not harm the healthy stem cells that produce blood, which is often the biggest risk with leukemia therapies. The only side effect observed was a temporary reduction in monocytes, a type of white blood cell, which the body can usually recover from.
Perhaps the most promising finding was how this new approach could be combined with existing strategies. The researchers noticed that the LILRB2 protein and another common target, CD117, rarely appear on the same cancer cell. This means that some leukemia cells hide from LILRB2-targeted attacks by not having the protein, while others hide from CD117-targeted attacks. By using both types of engineered T-cells together, the researchers could cover a much wider range of the cancer population. In tests with patient samples, this combination approach killed significantly more cancer cells than either treatment used alone. This suggests that a future therapy might involve a cocktail of different engineered cells, each targeting a different weakness, to ensure that no cancer cell can escape.
The study does not claim that this is a cure for everyone, but it provides a clear path forward for a treatment that has been difficult to develop. The researchers showed that LILRB2 is not just a marker on the cancer cell, but an active participant in the cancer's defense system. By targeting it, they were able to turn the cancer's own shield against it. The work highlights that the key to beating this disease may lie in understanding the specific signals the cancer uses to disable the immune system and designing therapies that can bypass or block those signals. While more testing is needed before this can be used in hospitals, the results offer a tangible reason for hope, showing that it is possible to engineer a treatment that is both powerful against the cancer and gentle enough to spare the healthy blood-making system.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.